Stephen P. Squinto
Président chez Chemomab Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Saqib Islam | M | 54 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 11 ans |
Carl Gordon | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 ans |
David Baram | M | - |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel.
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 11 ans |
Vered Bisker-Leib | M | 53 | 7 ans | |
Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 11 ans |
George Yancopoulos | M | 64 | 36 ans | |
Nissim Darvish | M | 59 |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel.
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 9 ans |
Dave Grayzel | M | 56 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
John Houston | M | 64 | 7 ans | |
Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
Leonard Schleifer | M | 71 | 36 ans | |
Julie Hambleton | M | 66 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 ans |
Edgar Cale | M | 60 | 5 ans | |
Randy Teel | M | 45 | 6 ans | |
David Feldman | M | - |
GlyGenix Therapeutics, Inc.
GlyGenix Therapeutics, Inc. BiotechnologyHealth Technology GlyGenix Therapeutics, Inc. focuses on treating and curing Glycogen storage diseases. The firm’s services include development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen storage disease type 1a. The company was founded by David Feldman and Peter Kaufman in 2006 and is headquartered in Woodbridge, CT.
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 18 ans |
Adi Mor | M | 43 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 13 ans |
Alan Fuhrman | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 5 ans |
Jeffrey Schwartz | M | 45 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 ans |
Maxine Gowen | M | 66 | 3 ans | |
Shoba Murali | F | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | - |
Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 ans |
Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
Claude Nicaise | M | 71 | 10 ans | |
Shilo Ben-Zeev | M | 50 |
SmartZyme Biopharma, Inc.
SmartZyme Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services SmartZyme Biopharma, Inc. provides platform for protein design and engineering in accordance with industry required specifications. The company was founded by David Baram and Shilo Ben Zeev in 2013 and is headquartered in Ness Ziona, Israel. | - |
Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
Paul Carter | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 ans |
Deval Patrick | M | 67 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 3 ans |
Murray Stewart | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 ans |
Damien McDevitt | M | 57 |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | 3 ans |
Freda Lewis-Hall | M | 69 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 7 ans |
Andres Bratt-Leal | M | - |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | - |
Bruce Turner | M | 60 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 ans |
Badreddin Edris | M | 37 | 6 ans | |
Todd Wider | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 6 ans |
James Sullivan | M | - |
Chamishi Therapeutics, Inc.
Chamishi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chamishi Therapeutics, Inc. is a drug discovery and development company. The company is headquartered in Deerfield, IL. | - |
Lior Izhar | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 ans |
Rachel Diamant | F | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 ans |
Elena Sukacheva | F | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | 2 ans |
Jamie Kramer | F | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | 30 ans |
Kim Diamond | F | - | 6 ans | |
Ian Taylor | M | 61 | 8 ans | |
Steve Weiss | M | 55 | 11 ans | |
Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 ans |
James M. Wilson | M | - | 7 ans | |
Jonathan Anderman | M | - | 3 ans | |
Mary Gray | M | 71 | 2 ans | |
Peter Kaufman | M | - |
The UCAN Co.
The UCAN Co. Food RetailRetail Trade The UCAN Co. manufactures energy drink for sports nutrition. The company is headquartered in Woodbridge, CT. | - |
Roger Abravanel | M | 77 | 3 ans | |
Herschel Weinstein | M | 68 | 4 ans | |
Ellen Chiniara | F | 65 | 2 ans | |
Carlos Alban | M | 61 | 2 ans | |
Michael Brown | M | 82 | 33 ans | |
Joseph Goldstein | M | 83 | 33 ans | |
George Sing | M | 74 | 36 ans | |
Neil Stahl | M | 67 | 33 ans | |
Phil Ferneau | M | 62 | 9 ans | |
Anthony Marucci | M | 62 | 3 ans | |
Andrew Spaventa | M | 39 |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | 6 ans |
Joseph Truitt | M | 59 |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | - |
Briggs Morrison | M | 65 | 6 ans | |
Alan Moses | M | 76 | 3 ans | |
Athena Countouriotis | M | 52 | 4 ans | |
Stuart M. Henderson | M | - | 3 ans | |
Edward Kennedy | M | 62 | 6 ans | |
Bill Lundberg | M | 60 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 5 ans |
Shelia Violette | M | - |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 7 ans |
Jodie Morrison | F | 48 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 2 ans |
V. Michael Holers | M | - |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
Shelley Chu | M | 54 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
Larry Lee | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | - |
Mark Iwicki | M | 57 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 4 ans |
Vincent Lu | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | - |
Luke Sikora | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | 3 ans |
Brian Van Elslander | M | - |
JPMorgan Asset Management Private Equity
JPMorgan Asset Management Private Equity Investment ManagersFinance JPMorgan Asset Management Private Equity (JPMorgan Asset Mgmt) is a private equity subsidiary of JPMorgan Investment Management, Inc founded in 1900. The firm is headquartered in New York. | - |
Jason A. Campagna | M | 54 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
Sarah Marshall | F | - | 10 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Leonard Bell | M | 65 |
Biotechnology Research & Development Corp.
Biotechnology Research & Development Corp. Miscellaneous Commercial ServicesCommercial Services Biotechnology Research & Development Corp. provides research on animal and plant healthcare, material sciences and biotechnology. The company is headquartered in Peoria, IL. | 25 ans |
David Brennan | M | 70 | 7 ans | |
Alfred G. Gilman | M | 82 | - | |
Eric M. Shooter | M | 100 | 26 ans | |
Michael V. Greco | M | 53 | 12 ans | |
Joseph A. Madri | M | 80 | 22 ans | |
Bruce Goldsmith | M | 58 | 2 ans | |
Liam Ratcliffe | M | 60 | 7 ans | |
David Hallal | M | 57 | 10 ans | |
Natalie Holles | F | 51 | 6 ans | |
Thomas Soloway | M | 55 | - | |
Jill Quigley | F | 49 |
Nutrinia Ltd.
Nutrinia Ltd. Pharmaceuticals: MajorHealth Technology Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel. | 5 ans |
Kory Wentworth | M | 45 | 9 ans | |
Lara Sullivan | M | 51 |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | 1 ans |
Dale Pfost | M | - | 2 ans | |
David W. Keiser | M | 72 | 16 ans | |
Lisa Lejuwaan | F | - | - | |
Rockford Norby | M | 88 | 18 ans | |
Jack Mollen | M | 73 | 7 ans | |
Mark Day | M | 52 | 2 ans | |
William Keller | M | 75 | 6 ans | |
Andreas Rummelt | M | 66 | 11 ans | |
Scott Peters | M | - | 8 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 89 | 89,00% |
Suisse | 8 | 8,00% |
Israël | 6 | 6,00% |
Italie | 2 | 2,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Stephen P. Squinto
- Réseau Personnel